Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

verfasst von

Michael Gerckens, Kenji Schorpp, Francesco Pelizza, Melanie Wögrath, Kora Reichau, Huilong Ma, Armando Marco Dworsky, Arunima Sengupta, Mircea Gabriel Stoleriu, Katharina Heinzelmann, Juliane Merl-Pham, Martin Irmler, Hani N. Alsafadi, Eduard Trenkenschuh, Lenka Sarnova, Marketa Jirouskova, Wolfgang Frieß, Stefanie M. Hauck, Johannes Beckers, Nikolaus Kneidinger, Jürgen Behr, Anne Hilgendorff, Kamyar Hadian, Michael Lindner, Melanie Königshoff, Oliver Eickelberg, Martin Gregor, Oliver Plettenburg, Ali Önder Yildirim, Gerald Burgstaller

Abstract

Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological processes involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts to an advanced three-dimensional phenotypic high-content assay and screened a repurposing drug library of small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection by Artificial Intelligence identified tranilast as an effective inhibitor. Structure-activity relationship studies confirmed N-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular contractility, and altered cell shapes, thus advocating a unique mode of action. Mechanistically, transcriptomics identified SMURF2 as a potential therapeutic target network. Antifibrotic activity of N23Ps was verified by proteomics in a human ex vivo tissue fibrosis disease model, suppressing profibrotic markers SERPINE1 and CXCL8. Conclusively, N23Ps are a novel class of highly potent compounds inhibiting organ fibrosis in patients.

Organisationseinheit(en)

Institut für Organische Chemie
Zentrum für Biomolekulare Wirkstoffe (BMWZ)

Externe Organisation(en)

Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
University of Strathclyde
Asklepios Fachkliniken München-Gauting
University of Pittsburgh
Ludwig-Maximilians-Universität München (LMU)
Akademie Věd České Republiky (AV ČR)
Deutsches Zentrum für Diabetesforschung e.V. (DZD)
Technische Universität München (TUM)
Paracelsus Private Medical University
Justus-Liebig-Universität Gießen
Lund University

Typ

Artikel

Journal

Science advances

Band

7

ISSN

2375-2548

Publikationsdatum

22.12.2021

Publikationsstatus

Veröffentlicht

Peer-reviewed

Ja

ASJC Scopus Sachgebiete

Allgemein

Ziele für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Elektronische Version(en)

https://doi.org/10.1126/sciadv.abb3673 (Zugang: Offen)